Skip to content

Total Equity at other companies

ALN
Alnylam PharmaceuticalsALNY
$1.08B+152%
Septerna, Inc. logo
Septerna, Inc.SEPN
$378.46M+195%
Regenxbio logo
RegenxbioRGNX
$21.08M-92.3%
Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
$101.31M+48.7%
Opko Health logo
Opko HealthOPK
$1.2B-8.2%
Ginkgo Bioworks logo
Ginkgo BioworksDNA
$443.15M-31.6%

Other financials

Income statement

See full
Operating income-$27.3M-49.2%
Net income-$25.2M-58.7%
EPS (diluted)-$1.34-44.1%

Balance sheet

See full
Cash & equivalents$236.9M-22.8%
Total debt$4.9M+86.1%
Total assets$246.6M-21.7%

Cash flow

See full
Operating cash flow-$18.4M-40.7%
CapEx$19.0K-29.6%
Free cash flow-$18.4M-40.6%

Valuation

See full
Market cap$585.51M+58.3%
Enterprise value$353.51M+438%

Returns & leverage

See full
Return on equity-31.4%
Debt / equity0.0×
Current ratio18.5×-4.4×

Where this comes from

Reported directly by Tectonic Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The official record: Tectonic Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tectonic Therapeutics's total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Tectonic Therapeutics's total equity?
Tectonic Therapeutics (TECX) reported total equity of $230.42M in Q1 2026.
How has Tectonic Therapeutics's total equity changed year-over-year?
Tectonic Therapeutics's total equity decreased by 23.5% year-over-year, from $301.04M to $230.42M.
What is the long-term trend for Tectonic Therapeutics's total equity?
Over 5 years (2020 to 2025), Tectonic Therapeutics's total equity has grown at a -0.2% compound annual growth rate (CAGR), from $254.34M to $251.33M.
What does total equity mean?
Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.